Toll Free: 1-888-928-9744

Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2016

Published: Mar 30, 2016 | Pages: 166 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2016', provides an overview of the Human papillomavirus (HPV) Associated Cancer pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Human papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer
- The report reviews pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Human papillomavirus (HPV) Associated Cancer therapeutics and enlists all their major and minor projects
- The report assesses Human papillomavirus (HPV) Associated Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Human papillomavirus (HPV) Associated Cancer Overview 9 Therapeutics Development 10 Pipeline Products for Human papillomavirus (HPV) Associated Cancer - Overview 10 Pipeline Products for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis 11 Human papillomavirus (HPV) Associated Cancer - Therapeutics under Development by Companies 12 Human papillomavirus (HPV) Associated Cancer - Therapeutics under Investigation by Universities/Institutes 14 Human papillomavirus (HPV) Associated Cancer - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Human papillomavirus (HPV) Associated Cancer - Products under Development by Companies 18 Human papillomavirus (HPV) Associated Cancer - Products under Investigation by Universities/Institutes 21 Human papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 22 3SBio Inc. 22 Admedus Ltd 23 Advaxis, Inc. 24 Antigen Express, Inc. 25 Bionor Pharma ASA 26 Cancer Research Technology Limited 27 Cancer Therapeutics CRC Pty Ltd 28 Chong Kun Dang Pharmaceutical Corp. 29 Etubics Corporation 30 EyeGene, Inc. 31 Formune S.L. 32 Genexine, Inc. 33 Genticel S.A. 34 iBio, Inc. 35 Immunovaccine, Inc. 36 Inovio Pharmaceuticals, Inc. 37 Inthera Bioscience AG 38 Karyopharm Therapeutics, Inc. 39 Kite Pharma, Inc. 40 MedImmune, LLC 41 Novartis AG 42 Onconova Therapeutics, Inc. 43 Oryx GmbH & Co. KG 44 Profectus BioSciences, Inc. 45 Selecta Biosciences, Inc. 46 Shantha Biotechnics Limited 47 Sirnaomics, Inc. 48 Theravectys SA 49 Transgene SA 50 UbiVac, LLC 51 Vaccibody AS 52 Virometix AG 53 ViroStatics, srl 54 VLPbio 55 Human papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 56 Assessment by Monotherapy Products 56 Assessment by Target 57 Assessment by Mechanism of Action 59 Assessment by Route of Administration 61 Assessment by Molecule Type 63 Drug Profiles 65 ABI-1968 - Drug Profile 65 AEH-10p - Drug Profile 66 alpelisib - Drug Profile 67 Antibodies to Target E6 for HPV Associated Cancer - Drug Profile 69 Antibodies to Target E7 for HPV Associated Cancer - Drug Profile 70 Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 71 Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer - Drug Profile 72 CerviVax - Drug Profile 74 CKD-12201 - Drug Profile 75 CTX-0197195 - Drug Profile 76 CTX-0272859 - Drug Profile 77 CTX-0291736 - Drug Profile 78 DPV-001 - Drug Profile 79 DPXE-7 - Drug Profile 81 EDA-HPVE7 - Drug Profile 82 EG-HPV - Drug Profile 83 ETBX-041 - Drug Profile 84 GTL-001 - Drug Profile 85 GTL-002 - Drug Profile 87 GX-188E - Drug Profile 88 HIV and HPV associated cancer vaccine - Drug Profile 89 human papillomavirus (7-valent) vaccine - Drug Profile 90 human papillomavirus [Serotype 16] vaccine - Drug Profile 91 human papillomavirus vaccine - Drug Profile 92 human papillomavirus vaccine - Drug Profile 93 human papillomavirus vaccine - Drug Profile 94 human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile 95 INO-3106 - Drug Profile 96 INO-3112 - Drug Profile 97 Lm-LLO-ISG15 - Drug Profile 99 LN-145 - Drug Profile 101 NIT-02 - Drug Profile 103 NP-001 - Drug Profile 104 PVX-01 - Drug Profile 105 Recombinant Vector Vaccine for HPV Associated Cervical Cancer - Drug Profile 106 Recombinant Vector Vaccine to Target E7 for HPV Associated Cancer - Drug Profile 107 Recombinant Vector Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile 108 rigosertib sodium - Drug Profile 109 sdCMV-002 - Drug Profile 114 SEL-701 - Drug Profile 115 Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers - Drug Profile 116 Small Molecules for Solid Tumors and HPV Associated Cancer - Drug Profile 117 SSS-08 - Drug Profile 118 STP-909 - Drug Profile 119 STP-911 - Drug Profile 120 Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile 121 TA-CIN - Drug Profile 122 TG-4001 - Drug Profile 124 TVGV-1 - Drug Profile 126 Vacc-HPV - Drug Profile 127 Vaccine for HPV Associated Cancer - Drug Profile 128 Vaccine for HPV Associated Cancers - Drug Profile 129 Vaccine for HPV Associated Skin Cancer - Drug Profile 130 Vaccine for Human papillomavirus Associated Cervical Cancer - Drug Profile 131 VB-1016 - Drug Profile 132 verdinexor - Drug Profile 133 VGX-3100 - Drug Profile 134 Vicoryx - Drug Profile 135 VMT-2 - Drug Profile 136 Human papillomavirus (HPV) Associated Cancer - Recent Pipeline Updates 137 Human papillomavirus (HPV) Associated Cancer - Dormant Projects 156 Human papillomavirus (HPV) Associated Cancer - Product Development Milestones 158 Featured News & Press Releases 158 Appendix 161 Methodology 161 Coverage 161 Secondary Research 161 Primary Research 161 Expert Panel Validation 161 Contact Us 161 Disclaimer 162
List of Tables
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H1 2016 14 Number of Products under Development for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 16 Number of Products under Development by Companies, H1 2016 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H1 2016 18 Comparative Analysis by Late Stage Development, H1 2016 19 Comparative Analysis by Clinical Stage Development, H1 2016 20 Comparative Analysis by Early Stage Development, H1 2016 21 Products under Development by Companies, H1 2016 22 Products under Development by Companies, H1 2016 (Contd..1) 23 Products under Development by Companies, H1 2016 (Contd..2) 24 Products under Investigation by Universities/Institutes, H1 2016 25 Human papillomavirus (HPV) Associated Cancer - Pipeline by 3SBio Inc., H1 2016 26 Human papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H1 2016 27 Human papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis, Inc., H1 2016 28 Human papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express, Inc., H1 2016 29 Human papillomavirus (HPV) Associated Cancer - Pipeline by Bionor Pharma ASA, H1 2016 30 Human papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Research Technology Limited, H1 2016 31 Human papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2016 32 Human papillomavirus (HPV) Associated Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 33 Human papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corporation, H1 2016 34 Human papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene, Inc., H1 2016 35 Human papillomavirus (HPV) Associated Cancer - Pipeline by Formune S.L., H1 2016 36 Human papillomavirus (HPV) Associated Cancer - Pipeline by Genexine, Inc., H1 2016 37 Human papillomavirus (HPV) Associated Cancer - Pipeline by Genticel S.A., H1 2016 38 Human papillomavirus (HPV) Associated Cancer - Pipeline by iBio, Inc., H1 2016 39 Human papillomavirus (HPV) Associated Cancer - Pipeline by Immunovaccine, Inc., H1 2016 40 Human papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 41 Human papillomavirus (HPV) Associated Cancer - Pipeline by Inthera Bioscience AG, H1 2016 42 Human papillomavirus (HPV) Associated Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 43 Human papillomavirus (HPV) Associated Cancer - Pipeline by Kite Pharma, Inc., H1 2016 44 Human papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune, LLC, H1 2016 45 Human papillomavirus (HPV) Associated Cancer - Pipeline by Novartis AG, H1 2016 46 Human papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics, Inc., H1 2016 47 Human papillomavirus (HPV) Associated Cancer - Pipeline by Oryx GmbH & Co. KG, H1 2016 48 Human papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences, Inc., H1 2016 49 Human papillomavirus (HPV) Associated Cancer - Pipeline by Selecta Biosciences, Inc., H1 2016 50 Human papillomavirus (HPV) Associated Cancer - Pipeline by Shantha Biotechnics Limited, H1 2016 51 Human papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics, Inc., H1 2016 52 Human papillomavirus (HPV) Associated Cancer - Pipeline by Theravectys SA, H1 2016 53 Human papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H1 2016 54 Human papillomavirus (HPV) Associated Cancer - Pipeline by UbiVac, LLC, H1 2016 55 Human papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H1 2016 56 Human papillomavirus (HPV) Associated Cancer - Pipeline by Virometix AG, H1 2016 57 Human papillomavirus (HPV) Associated Cancer - Pipeline by ViroStatics, srl, H1 2016 58 Human papillomavirus (HPV) Associated Cancer - Pipeline by VLPbio, H1 2016 59 Assessment by Monotherapy Products, H1 2016 60 Number of Products by Stage and Target, H1 2016 62 Number of Products by Stage and Mechanism of Action, H1 2016 64 Number of Products by Stage and Route of Administration, H1 2016 66 Number of Products by Stage and Molecule Type, H1 2016 68 Human papillomavirus (HPV) Associated Cancer Therapeutics - Recent Pipeline Updates, H1 2016 141 Human papillomavirus (HPV) Associated Cancer - Dormant Projects, H1 2016 160 Human papillomavirus (HPV) Associated Cancer - Dormant Projects (Contd..1), H1 2016 161


List of Figures
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H1 2016 14 Number of Products under Development for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 16 Number of Products under Investigation by Universities/Institutes, H1 2016 18 Comparative Analysis by Clinical Stage Development, H1 2016 20 Comparative Analysis by Early Stage Products, H1 2016 21 Assessment by Monotherapy Products, H1 2016 60 Number of Products by Top 10 Targets, H1 2016 61 Number of Products by Stage and Top 10 Targets, H1 2016 61 Number of Products by Mechanism of Actions, H1 2016 63 Number of Products by Stage and Mechanism of Actions, H1 2016 63 Number of Products by Top 10 Routes of Administration, H1 2016 65 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 65 Number of Products by Top 10 Molecule Types, H1 2016 67 Number of Products by Stage and Top 10 Molecule Types, H1 2016 67

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...

Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.

Read More...

Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likely

Read More...

Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expe

Read More...

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify